DE60030770D1 - Verwendung von taurolidin oder taurultam zur herstellung eines medikaments zur behandlung von ovarialkarzinomen - Google Patents

Verwendung von taurolidin oder taurultam zur herstellung eines medikaments zur behandlung von ovarialkarzinomen

Info

Publication number
DE60030770D1
DE60030770D1 DE60030770T DE60030770T DE60030770D1 DE 60030770 D1 DE60030770 D1 DE 60030770D1 DE 60030770 T DE60030770 T DE 60030770T DE 60030770 T DE60030770 T DE 60030770T DE 60030770 D1 DE60030770 D1 DE 60030770D1
Authority
DE
Germany
Prior art keywords
neoplastic cell
carcinomes
taurultam
taurolidine
ovarian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60030770T
Other languages
English (en)
Other versions
DE60030770T2 (de
Inventor
Paul Calabresi
James Darnowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geistlich Pharma AG
Original Assignee
Rhode Island Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27389609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60030770(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhode Island Hospital filed Critical Rhode Island Hospital
Application granted granted Critical
Publication of DE60030770D1 publication Critical patent/DE60030770D1/de
Publication of DE60030770T2 publication Critical patent/DE60030770T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60030770T 1999-12-06 2000-12-06 Verwendung von taurolidin oder taurultam zur herstellung eines medikaments zur behandlung von ovarialkarzinomen Expired - Lifetime DE60030770T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16912899P 1999-12-06 1999-12-06
US16912299P 1999-12-06 1999-12-06
US16912799P 1999-12-06 1999-12-06
US169128P 1999-12-06
US169122P 1999-12-06
US169127P 1999-12-06
PCT/US2000/033103 WO2001039762A2 (en) 1999-12-06 2000-12-06 Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system

Publications (2)

Publication Number Publication Date
DE60030770D1 true DE60030770D1 (de) 2006-10-26
DE60030770T2 DE60030770T2 (de) 2007-09-06

Family

ID=27389609

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60030770T Expired - Lifetime DE60030770T2 (de) 1999-12-06 2000-12-06 Verwendung von taurolidin oder taurultam zur herstellung eines medikaments zur behandlung von ovarialkarzinomen

Country Status (9)

Country Link
US (6) US6521616B2 (de)
EP (3) EP1248625A2 (de)
JP (5) JP5027369B2 (de)
AT (1) ATE339207T1 (de)
AU (2) AU784539B2 (de)
CA (3) CA2393159C (de)
DE (1) DE60030770T2 (de)
ES (2) ES2531547T3 (de)
WO (2) WO2001039763A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479481B1 (en) * 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US20070275955A1 (en) * 1997-07-31 2007-11-29 Ed. Geistlich Soehne Ag Method of treating tumors
US20060199811A1 (en) * 1997-07-31 2006-09-07 Pfirrmann Rolf W Method of treatment for preventing or reducing tumor growth in the liver of patient
US20030027818A1 (en) 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US8030301B2 (en) 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US20030225067A1 (en) * 1999-06-04 2003-12-04 Ruediger Stendel Microdialysis methods and applications for treatment and/or prophylaxis of tumors and/or infections in the central nervous system (CNS) and/or in other parenchymal organs
US20020098164A1 (en) 2000-10-27 2002-07-25 Redmond H. Paul Treatment of tumor metastases and cancer
EP1797884B1 (de) * 1999-12-06 2013-09-11 Geistlich Pharma AG Taurolidin oder Taurultam zur Verwendung bei der Behandlung von Tumoren der Prostata, des Kolons, der Lungen und von wiederkehrendem Glioblastoma multiforme.
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
EP1248625A2 (de) * 1999-12-06 2002-10-16 Rhode Island Hospital Verwendung von methylol-enthaltenden verbindungen zur herstellung eines medikaments zur behandlung von tumoren
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
GB0104383D0 (en) * 2001-02-22 2001-04-11 Psimedica Ltd Cancer Treatment
CA2441016A1 (en) * 2001-03-15 2002-09-26 Paul Calabresi Taurine compounds
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
US20080171738A1 (en) * 2001-04-03 2008-07-17 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of Breast Cancer
CA2462564C (en) * 2001-10-01 2012-07-10 Rhode Island Hospital Methods of inhibiting metastases
CA2412012C (en) 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
ES2268286T3 (es) * 2002-03-21 2007-03-16 Ed. Geistlich Sohne Ag Fur Chemische Industrie Aparato para el tratamineto de un tumor en el sistema nervioso central.
PT1545534E (pt) * 2002-09-24 2007-06-22 Novartis Ag Utilização de derivados de 4-piridilmetil-ftalazina para o fabrico de um medicamento para o tratamento de síndromes mielodisplásicos
US7167750B2 (en) * 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
AU2004201264B2 (en) * 2003-03-28 2009-12-24 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Adhesive Antineoplastic Compositions
US20050008684A1 (en) * 2003-07-10 2005-01-13 Claus Herdeis Method of treatment for acne, rosacea and ulcers with taurolidine and/or taurultam in a pharmaceutical composition
CA2482687C (en) * 2003-09-29 2012-11-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
US20080177217A1 (en) * 2004-05-14 2008-07-24 Hans-Dietrich Polaschegg Taurolidine Formulations and Delivery: Therapeutic Treatments and Antimicrobial Protection Against Bacterial Biofilm Formation
WO2006009765A2 (en) * 2004-06-18 2006-01-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
CA2790675C (en) * 2005-07-19 2016-12-20 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
WO2007020509A1 (en) * 2005-08-15 2007-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth
ES2377206T3 (es) * 2006-01-06 2012-03-23 Ed Geistlich Sohne Ag Fur Chemische Industrie Composiciones irradiadas y tratamiento de cánceres con radiación en combinación con taurolidina y/o taurultam
US20100291173A1 (en) * 2006-09-05 2010-11-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of improving renal function
EP2061429A2 (de) 2006-09-07 2009-05-27 Ed. Geistlich Söhne Ag Für Chemische Industrie Verfahren zur behandlung von knochenkrebs
EP2240175B1 (de) * 2008-02-11 2013-01-02 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Verbindungen mit mdr1-inverser aktivität
DE102010010360A1 (de) * 2010-03-05 2011-09-08 Gamptec Gmbh Formulierungen von Taurolidin und Verfahren zu seiner Herstellung
US9028866B2 (en) * 2010-06-01 2015-05-12 Geistlich Pharma Ag Methods and compositions for oral pharmaceutical therapy
EP2621458B1 (de) 2010-09-27 2017-04-19 Geistlich Pharma AG Antimikrobielle zahnpflegezubereitung
DK2861573T3 (da) 2012-06-18 2017-11-13 Geistlich Pharma Ag Oxathiazin-derivater som antibakterielle og anticancer-stoffer
JP2016539149A (ja) * 2013-12-06 2016-12-15 ノバルティス アーゲー アルファ−アイソフォーム選択的ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン
US20170100407A1 (en) * 2015-10-07 2017-04-13 Cormedix Inc. Skin-penetrating formulation of taurolidine
US11541061B2 (en) * 2016-01-11 2023-01-03 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products
CN108778339A (zh) * 2016-01-11 2018-11-09 科医公司 用于治疗神经母细胞瘤及其他癌症的治疗性纳米颗粒
US20190381058A1 (en) * 2016-01-11 2019-12-19 Cormedix Inc. Methods and compositions for treating neuroblastoma in a juvenile mammalian body
WO2018126133A1 (en) * 2016-12-29 2018-07-05 Cormedix Inc. Skin-penetrating formulation of taurolidine
CN109929804B (zh) * 2017-12-15 2020-10-16 天津医科大学肿瘤医院 一种人卵巢癌细胞系及其制备方法和应用
AU2019330954A1 (en) * 2018-08-28 2021-04-22 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products
KR20210050543A (ko) * 2018-08-28 2021-05-07 코르메딕스, 인코포레이티드 유년기 포유류 신체내의 신경모세포종을 치료하기 위한 방법 및 조성물
WO2020047530A1 (en) * 2018-08-31 2020-03-05 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
US20220323452A1 (en) 2019-05-22 2022-10-13 Geistlich Pharma Ag Methods and compositions for inhibiting gapdh
WO2020234833A1 (en) 2019-05-22 2020-11-26 Geistlich Pharma Ag Method for treating, preventing, inhibiting or reducing cytokine release

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1124285A (en) 1964-10-06 1968-08-21 Geistlich Soehne Ag Novel perhydro-1,2,4-thiadiazine dioxides-(1,1), their preparation and compositionscontaining them
GB1408010A (en) 1972-11-20 1975-10-01 Geistlich Soehne Ag Sulphamoylphenyl-imidazolidinones
GB1557163A (en) 1975-06-24 1979-12-05 Geistlich Soehne Ag Dental care preparations
US4107305A (en) * 1975-08-04 1978-08-15 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Treatment of endotoxaemia
GB1588110A (en) 1978-05-31 1981-04-15 Geistlich Soehne Ag Pharmaceutical compositions for the treatment of scars
US4192302A (en) * 1978-09-12 1980-03-11 Boddie Arthur W Hepatic isolation and perfusion circuit assembly
JPS5598170A (en) * 1979-01-18 1980-07-25 Mitsui Toatsu Chem Inc 5-fluorouracil derivative and its preparation
US4337251A (en) * 1979-05-09 1982-06-29 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of avoiding and removing adhesions
CA1190855A (en) 1980-09-03 1985-07-23 Rolf W. Pfirrmann Treatment of osteitis
GB8328111D0 (en) 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
GB8328073D0 (en) 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
GB8328074D0 (en) 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compositions
US5206352A (en) * 1986-03-28 1993-04-27 Board Of Trustees Of The University Of Illinois Compositions for clones containing DNA sequences associated with multidrug resistance in human cells
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
US5573771A (en) 1988-08-19 1996-11-12 Osteomedical Limited Medicinal bone mineral products
GB8827986D0 (en) 1988-11-30 1989-01-05 Geistlich Soehne Ag Chemical product
US5819748A (en) 1988-11-30 1998-10-13 Ed Geistlich Sohne Ag Fur Chemische Industrie Implant for use in bone surgery
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
GB9005856D0 (en) 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
GB9015108D0 (en) * 1990-07-09 1990-08-29 Geistlich Soehne Ag Chemical compositions
DE69104608T2 (de) * 1991-07-04 1995-02-16 Weissenfluh Hawe Neos Pharmazeutische Zubereitungen, Clavulansäure enthaltend, für die Behandlung der Periodontitis.
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
GB9216155D0 (en) 1992-07-30 1992-09-09 Geistlich Soehne Ag Treatment of dentoalveolar infections
FR2728790B1 (fr) * 1994-12-29 1997-01-24 Cird Galderma Composition modulant l'apoptose comprenant du methonial ou tout facteur influencant le taux intracellulaire de methonial
US5954687A (en) * 1995-04-28 1999-09-21 Medtronic, Inc. Burr hole ring with catheter for use as an injection port
US5976822A (en) 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
GB9600426D0 (en) 1996-01-10 1996-03-13 Ed Geistlich Sohne A G Compositions
DE19606897C2 (de) * 1996-02-13 2002-08-29 Geistlich Soehne Ag Mittel zur Verhinderung der Tumorzellverschleppung und der Entstehung von Trokarmetastasen in der offenen und laparoskopischen Chirurgie maligner Tumoren
CA2290537C (en) * 1997-05-22 2007-10-02 Oklahoma Medical Research Foundation Use of taurolidine for treatment of leukemias
GB9716219D0 (en) 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US6479481B1 (en) * 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US6011030A (en) 1997-09-22 2000-01-04 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating symptoms of microbial infection or sepsis
US5972933A (en) 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
US6117868A (en) 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
EP1248625A2 (de) * 1999-12-06 2002-10-16 Rhode Island Hospital Verwendung von methylol-enthaltenden verbindungen zur herstellung eines medikaments zur behandlung von tumoren
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose

Also Published As

Publication number Publication date
US20020049200A1 (en) 2002-04-25
US6995164B2 (en) 2006-02-07
EP1248625A2 (de) 2002-10-16
DE60030770T2 (de) 2007-09-06
WO2001039762A3 (en) 2002-05-02
JP2003515558A (ja) 2003-05-07
CA2393252A1 (en) 2001-06-07
US20020111345A1 (en) 2002-08-15
JP2014198739A (ja) 2014-10-23
JP2012136540A (ja) 2012-07-19
AU784538B2 (en) 2006-04-27
JP6234340B2 (ja) 2017-11-22
US6521616B2 (en) 2003-02-18
ES2531547T3 (es) 2015-03-17
US6703413B2 (en) 2004-03-09
EP2332542A2 (de) 2011-06-15
US6964959B2 (en) 2005-11-15
US6429224B1 (en) 2002-08-06
CA2393159A1 (en) 2001-06-07
CA2696185A1 (en) 2001-06-07
EP2332542A3 (de) 2011-09-28
JP5027369B2 (ja) 2012-09-19
ATE339207T1 (de) 2006-10-15
EP1246617A2 (de) 2002-10-09
CA2393159C (en) 2010-04-20
JP5829948B2 (ja) 2015-12-09
JP2003515557A (ja) 2003-05-07
AU784539B2 (en) 2006-04-27
AU2064901A (en) 2001-06-12
WO2001039763A2 (en) 2001-06-07
US20030100551A1 (en) 2003-05-29
WO2001039762A2 (en) 2001-06-07
US20030078257A1 (en) 2003-04-24
WO2001039763A3 (en) 2002-07-11
EP2332542B1 (de) 2015-02-11
CA2696185C (en) 2014-09-23
US20020052366A1 (en) 2002-05-02
US20060135513A1 (en) 2006-06-22
AU2065001A (en) 2001-06-12
EP1246617B1 (de) 2006-09-13
JP2016188244A (ja) 2016-11-04
ES2438535T3 (es) 2014-01-17

Similar Documents

Publication Publication Date Title
DE60030770D1 (de) Verwendung von taurolidin oder taurultam zur herstellung eines medikaments zur behandlung von ovarialkarzinomen
DK1131096T3 (da) Anti-CD20-antistofbehandling af patienter, der modtager knoglemarvs- eller periferisk blodstamcelletransplantationer
DE60117043D1 (de) Behandlung von mukositis
DE602004012816D1 (de) Selbstexpandierbarer Stent und Stenteinbringungssystem zur Behandlung von Gefässerkrankungen
ATE204754T1 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE10085007T1 (de) Antiinfektionszusammensetzungen zur Behandlung von erkranktem Gewebe, wie Lippenherpes
BR0107942A (pt) Polìmeros de proteìna de liberação lenta
DE602006018845D1 (de) Gelenkeoberflächematerialen zur Herstellung von medizinische Implantate
ATE94387T1 (de) Verwendung von n-myristoyl-(s)-phenylalanin zur herstellung eines medikaments zur behandlung von krankheiten mittels hemmung der myristoylierung.
ATE339227T1 (de) Beschichtetes medizinsches implantat zur behandlung von gefässerkrankungen
ATE172711T1 (de) 2-amino-1, 3- propandiolverbindung und immunosuppressium
DE59905763D1 (de) Fumarsäurederivate zur behandlung der transplantatabstossung
PT1061940E (pt) Utilizacao de foliestatina para a producao de um medicamento para o tratamento de disturbios relacionados com os musculos
DE60210552D1 (de) Prozess zur Herstellung einer festen pharmazeutischen Zubereitung welche einen schwerlöslichen Wirkstoff enthält
NO20011283D0 (no) Anvendelse av integrin-antagonister ved behandling av multippelt myelom og myelom-indusert benresorpsjon
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
BR9907099A (pt) Composições farmacêuticas
ATE555748T1 (de) Antibiotische mikrokügelchen zur behandlung von infektionen und osteomyelitis
DE69917074D1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
ATE151288T1 (de) N-acetyl-cysteine derivate enthaltende pharmazeutische zusammensetzung zur behandlung von katarakt
DE60206245D1 (de) Verwendung von r-ibuprofen methanesulfonamied und dessen salzen zur behandlung und verhinderung von abstossungreaktionen in transplartierten organen
DE60213766D1 (de) Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE186214T1 (de) Verwendung von rosmanolderivaten zur herstellung von antiradikalischen und/oder antilipoperoxidativen und/oder hepatotropen arzneistoffen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: GEISTLICH PHARMA AG, WOLHUSEN, CH